Growth hormone treatment in pediatrics: What can we improve?

Growth hormone (GH) or somatotropin treatment is approved in Spain for the following indications: GH deficiency; impaired growth in chronic kidney disease (CKD); Turner's syndrome; Prader-Willi syndrome; Noonan syndrome; patients diagnosed as small for gestational age (SGA); and patients with abnormalities of the SHOX gene.1

The aim of the treatment is to increase growth rate (GR) and reach an adequate adult height within the growth potential of each patient2 and its effectiveness depends on both the indication and the age at which the treatment is started. For optimal efficacy, the treatment should be started as early as possible.3

The aims of this study were to analyse the age treatment is started in the different indications, assess the response and identify points for improvement.

留言 (0)

沒有登入
gif